Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL27197226 | 0.93 | MAPT (0.50) | MAPTALDH1A1LMNAPDK2GPR119 | |
| SCHEMBL20708147 | 0.92 | GPR119 (0.53) | MAPTALDH1A1LMNAPDK2GPR119 | |
| SCHEMBL3753571 | 0.90 | MAPT (0.50) | MAPTALDH1A1LMNAPDK2GPR119 | |
| SCHEMBL31036793 | 0.90 | MAPT (0.50) | MAPTALDH1A1LMNAPDK2GPR119 | |
| SCHEMBL19404228 | 0.89 | TTR (0.51) | MAPTALDH1A1LMNAPDK2GPR119 | |
| SCHEMBL30976319 | 0.87 | EGLN2 (0.53) | MAPTALDH1A1LMNAPDK2GPR119 | |
| SCHEMBL19404303 | 0.87 | MAPT (0.47) | MAPTALDH1A1LMNAPDK2GPR119 | |
| SCHEMBL20140111 | 0.87 | MAPT (0.54) | MAPTALDH1A1LMNAPDK2GPR119 | |
| SCHEMBL31036796 | 0.86 | MAPT (0.68) | MAPTALDH1A1LMNAPDK2GPR119 | |
| SCHEMBL2386747 | 0.86 | GPR119 (0.59) | MAPTALDH1A1LMNAPDK2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CENTAURUS THERAPEUTICS (US) | 2026-03-12 | — | — | US | disclosed |
| US-12247019-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2025-03-11 | — | — | US | disclosed |
| US-20240124400-A1 | LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME | DUKE UNIVERSITY (US) | 2024-04-18 | — | — | US | disclosed |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2023-11-09 | — | — | US | disclosed |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2023-11-09 | — | — | US | disclosed |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2023-11-09 | — | — | US | disclosed |
| CN-111787916-B | Dihydroceramide desaturase inhibitors for treating diseases | 森陶鲁斯治疗公司 | 2023-09-05 | — | — | CN | disclosed |
| US-11597715-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2023-03-07 | — | — | US | disclosed |
| US-11597715-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CENTAURUS THERAPEUTICS (US) | 2023-03-07 | — | — | US | disclosed |
| WO-2021072369-A1 | LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME | DUKE UNIVERSITY (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20200339535-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CENTAURUS THERAPEUTICS | 2020-10-29 | — | — | US | disclosed |
| CN-111787916-A | Inhibitors of dihydroceramide desaturase for the treatment of diseases | 森陶鲁斯治疗公司 | 2020-10-16 | — | — | CN | disclosed |
| US-20200147581-A1 | METHODS FOR FORMING ARYL CARBON-NITROGEN BONDS USING LIGHT AND PHOTOREACTORS USEFUL FOR CONDUCTING SUCH REACTIONS | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2020-05-14 | — | — | US | disclosed |
| EP-3575294-A1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | Les Laboratoires Servier (FR) | 2019-12-04 | — | — | EP | disclosed |
| US-20190345122-A1 | METHODS FOR FORMING ARYL CARBON-NITROGEN BONDS USING LIGHT AND PHOTOREACTORS USEFUL FOR CONDUCTING SUCH REACTIONS | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2019-11-14 | — | — | US | disclosed |
| EP-3237406-B1 | 5-[(PIPERAZIN-1-YL)-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-02-06 | — | — | EP | disclosed |
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | GLAXO GROUP LIMITED | 2008-10-16 | — | — | US | disclosed |
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | GLAXO GROUP LIMITED | 2008-10-16 | — | — | US | disclosed |
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | GLAXO GROUP LIMITED | 2008-10-16 | — | — | US | disclosed |
| WO-2006094842-A1 | ACYLATED PIPERIDIHES AS GLYCINE TRANSPORTER INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255144-A1 | Acylated Piperidines as Glycine Transporter Inhibitors | SLC1A1, SLC6A7, SLC1A2 | MAPT 762/4885ALDH1A1 1291/4885LMNA 4248/4885 |
| US-11597715-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CERS2, SMPD1, ASAH1 | MAPT 2085/4885ALDH1A1 1260/4885LMNA 1375/4885 |
| US-20260070884-A1 | Inhibitors of Dihydroceramide Desaturase for Treating Disease | CERS2, DEGS1, CERT1 | MAPT 4429/4885ALDH1A1 1500/4885LMNA 2016/4885 |
| US-20240124400-A1 | LPXH TARGETING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF MAKING AND USING THE SAME | CFH, LPAR3, CBR3 | MAPT 4754/4885ALDH1A1 3931/4885LMNA 512/4885 |
| US-12247019-B2 | Inhibitors of dihydroceramide desaturase for treating disease | CERS2, SMPD1, ASAH1 | MAPT 2085/4885ALDH1A1 1260/4885LMNA 1375/4885 |
| US-20200339535-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CERS2, SMPD1, ASAH1 | MAPT 2085/4885ALDH1A1 1260/4885LMNA 1375/4885 |
| US-20230357187-A1 | Inhibitors of Dihydroceramide Desaturase For Treating Disease | CERS2, SMPD1, ASAH1 | MAPT 2085/4885ALDH1A1 1260/4885LMNA 1375/4885 |
| US-20190345122-A1 | METHODS FOR FORMING ARYL CARBON-NITROGEN BONDS USING LIGHT AND PHOTOREACTORS USEFUL FOR CONDUCTING SUCH REACTIONS | TYR, CRY2, CRY1 | MAPT 3361/4885ALDH1A1 1574/4885LMNA 3378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.